Littleton, CO (September 6th, 2011) – Novus Biologicals, an international supplier of antibodies and antibody-related products to bioscience researchers, announce that they have ranked among Inc. magazine’s fastest-growing private companies.
On August 24th, Inc. magazine issued its fifth annual Inc. 5000 list; a prestigious ranking of the nation’s fastest-growing private companies. Novus Biologicals ranked among these companies for the 5th year in a row. This list honors the companies and their entrepreneurs who make a fundamental contribution to the future growth of the American economy.
“It is truly an honor to be listed as one of America’s fastest growing companies; to stand out in the industry for the past five years, attests to our continued commitment to our customers. We understand that our future success is dependent on keeping a sharp eye on the needs of our stakeholders,” stated Karen Padgett, President and CEO of Novus Biologicals.
Novus Biologicals provides high quality research products to government, university, and private sector biotechnology labs worldwide. They have increased their global presence with two international offices in the UK and Canada. In addition to their line of antibodies, Novus also provides peptides, proteins, lysates, antibody labeling kits, and additional support products to the bioscience industry.
Novus has experienced 3-year growth of 76%, ranking them at no. 248 in the Healthcare industry and no. 59 in Denver. An innovative product line, coupled with a commitment to excellence in customer service and support has helped Novus to place on the Inc. 5000 list for the fifth straight year (no. 3362 in 2007, no. 3062 in 2008, no. 2807 in 2009 and no. 2647 in 2010).
The 2011 Inc. 500 | 5000 is ranked according to percentage revenue growth when comparing 2006 to 2009. To qualify, companies must have been founded and generating revenue by June 30, 2006. Additionally, they had to be based in the United States, privately held, for profit, and independent – not a subsidiary or division of a larger conglomerate – as of December 31, 2009.
For more information on Novus Biologicals’ antibodies and related bioscience products, please visit www.novusbio.com.
About Novus Biologicals (www.novusbio.com)
Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science. Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community. The Novus Guarantee + Innovator’s Reward™ Policy 100% guarantees all of Novus’ products to work in the species and applications listed on the datasheet. Novus is a privately held company backed by Mainsail Partners (www.mainsailpartners.com), a San Francisco based private equity firm that invested in Novus in 2008. By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.
Nehal Saleh, PhD
Novus Biologicals Europe
12 Cambridge Science Park
Cambridge, CB4 0FQ, UK
Tel: +44 (0)1223 426001
Fax: +44 (0)871 971 1635
Novus Biologicals Worldwide
PO Box 802
Littleton, CO 80160 USA